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Raised levels of latent collagenase activating angiogenesis factor (ESAF)
are present in actively growing human intracranial tumours
C.M. Taylor', J.B. Weiss' & R.H. Lye2
Departments of 'Rheumatology and 2Neurosurgery, University ofManchester, Manchester M13 9PT, UK.
Summary Endothelial cell stimulating angiogenesis factor (ESAF) is a potent, low molecular mass mitogen,
specific for endothelial cells. In common with various protein growth factors, it displays angiogenic activity in
a variety of biological test systems. However, it differs from these other factors by virtue of its low molecular
mass and its ability to activate latent matrix metalloproteinases in a dose dependent manner. This activity has
been used to quantify the factor in both normal and diseased brain tissue. The concentration of ESAF
determined in biopsies from different types of intracranial tumours varied: in some tumour types the level was
close to that of control samples whereas in others it rose to levels comparable to those encountered in the
pineal gland, the richest source of ESAF in mature mammals. Tumours considered to be benign contained
significantly less ESAF than those neoplasms classified as being malignant (P = 0.025). There was also a
correlation between the mitotic activity of tumour samples, as detennined by conventional H & E his-
tochemical staining and the ESAF concentration present. These findings agree with previous studies in which
elevated ESAF levels have been found in tissue where proliferation of vascular elements has been observed.
The continual growth of a tumour beyond a critical size
relies on the development of new blood vessels (neovas-
cularisation) to maintain an adequate supply of nutrients for
the tumour cells (Folkman, 1984). It is known that tumours
produce several substances capable of inducing the prolifera-
tion and migration of host capillary endothelial cells. These
substances include fibroblast growth factors (Shing et al.,
1985; Klagsbrun et al., 1986), which are non-specific cell
mitogens widely distributed in neural and other tissues.
Recently it has been shown that the stimulation of micro-
vessel cell proliferation by these factors is enhanced if endo-
thelial cell stimulating angiogenesis factor (ESAF) is present
(Odedra & Weiss, 1987).
The molecular mass of ESAF is approximately 400 and its
angiogenic activity has been demonstrated in several test
systems (Weiss et al., 1987; Elstow et al., 1985). Unlike
protein growth factors, ESAF is a mitogen specifically for
microvessel cells (Schor et al., 1980). It enhances the chemo-
taxis and chemokinensis of microvessel, but not aortic endo-
thelial cells and has no effect on fibroblasts (Odedra and
Weiss in preparation). The synergism between fibroblast
growth factors and ESAF suggests the presence of the latter
may be vital for the in vivo stimulation of capillary growth.
It has been shown that ESAF activates latent collagenase
(Weiss et al., 1983) by reversing the inhibition of this enzyme
by tissue inhibitor of metalloproteinases (McLaughlin et al.,
1991). These findings suggest that ESAF has an important
role in the connective tissue destruction associated with blood
vessel penetration. It is also probable that ESAF is im-
plicated in the connective tissue breakdown associated with
the expansion of neoplasms.
Materials and methods
Assessment oftumours
At operation, as large a biopsy as possible was taken from
each tumour and stored at -20°C until processing for the
extraction of ESAF. Cautery was avoided when the biopsy
was obtained. As far as could be ascertained, the biopsy
samples taken were typical of the tumour under considera-
tion.
Tumour classification was based upon histological examin-
ation of biopsy specimens taken adjacent to the area where
the samples for ESAF determination had been obtained.
Tissue staining techniques used the standard haemotoxylin
and eosin method and samples were classifed as 'actively
growing' according to the number of mitotic figures seen,
areas of necrosis and vascularity (Vafardis et al., 1987).
Tumour and control brain samples
Biopsy samples of tumour tissue was obtained from 20
patients with benign or malignant intracranial tumours
(Tables I and II). Control brain tissue was obtained at
autopsy from a variety of non-tumour patients or from
patients with head injuries when damaged brain was resected
(Table III). Samples were frozen at - 20'C prior to extrac-
tion.
Extraction ofESAF
Individual samples were homogenised at 4'C in 50 mM
NH4HCO3 buffer (pH 7.9) containing 2 M Mg Cl2. After cen-
trifugation at 20000 g (1 h, 4'C) the supernatant was assayed
for protein (Lowry et al., 1951) prior to ultrafiltration on a
YM5 filter membrane (5000 Mr exclusion limit) (Amicon,
Stonehouse, Glou., UK) with five volumes of bicarbonate
buffer. The ultrafiltrate was reduced by rotary evaporation to
a volume of 5 ml and applied to an octodecyl silica column
(Analytichem, Harbor City, California, USA). Bound low
molecular mass material was eluted with methanol.
Assay of angiogenic material for its ability to activate
latent collagenase was performed according to the method of
Weiss et al. (1983). Results were expressed as 1tg collagen
degraded h-I mg-' protein in the supernatant.
The active material eluting from the octodecyl silica col-
umn passed readily through a membrane with an exclusion
limit of 3000 Mr. The apparent molecular mass was estab-
lished by gel filtration on a Bio-Gel P-2 (Weiss et al., 1979).
Angiogenic activity was assessed using the chick yolk sac
membrane test (Taylor & Weiss, 1984).
Latent collagenase activation assay
3H-labelled rat tail tendon collagen was prepared by a
modification of the method of Gisslow and McBride (1975).
Latent collagenase was prepared from the culture fluid of
human skin fibroblasts stimulated with cytochalasin B. After
concentration x 100 the fluid was applied to an ACA col-
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Table I Benign intracranial tumours
Sex Age Tumour site
M 71 Frontal
convexity
F 62 Olfractory
groove
M 65 Frontal
parasagittal
M 60 Frontal
convexity
F 60 Cerebello-
pontine angle
F 58 Pituitary
fossa
M 63 Pituitary
fossa
M 55 Pituitary
fossa
M 55 Cerebello-
pontine angle
M 37 Cerebello-
pontine angle
M 51 Cerebello-
pontine angle
F 27 Cerebello-
pontine angle
T
N
Pi
Pi
Pi
A
A
A
A
Histological
'umour type features
leningioma Psammomatous
leningioma Meningothelial
leningioma Meningothelial
leningioma Haemangioblastoma
4eningioma Fibrous
'ituitary Prolactinoma
ituitary GH-secreting
adenoma
ituitary FSH-secreting
adenoma
coustic Schwannoma
nerve tumour Antoni A & B
coustic Schwannoma
nerve tumour Antoni A & B
coustic Schwannoma
nerve tumour Antoni A & B
coustic Schwannoma
nerve tumour Antoni A & B
siJ
active
gns of Drug
? growtha treatment
+ Steroids +
folic acid
- Steroids
+ + None
- Steroids
+ Nifedipine
- Steroids
- Steroids
- Steroids
- Steroids
- Steroids
- None
- None
Recurrenceb
No
No
No
No
No
No
No
No
No
No
No
No
Mean ESAFcontent
gg collagen degraded
h-' mg-' protein
1.42
0.235
4.80
1.43
1.385
1.68
0.40
3.66
0.38
0.79
1.18
0.15
aAny one (+) or more (+ +) of: nuclear pleomorphism; cellular immaturity; tumour angiogenesis; tumour necrosis. bTo some extent recurrence
depends upon lengths of clinical follow up or survival.
Table II Malignant intracranial tumours
Mean ESAF content
Patient Histologicalc Signs of Drug ILg collagen degraded
no. Sex Age Tumour site Tumour type features active growtha treatment Recurrenceb h-' mg-' protein
13 M 45 Occipital lobe Glioma Astrocytoma + Steroids Died 1.40
Grade III
14 M 57 Temporal Glioma Astrocytoma + + Steroids Yes 1.94
lobe Grade IV
15 M 66 Frontal lobe Glioma Astrocytoma + + Steroids Died 4.05
Grade III-IV
16 F 65 Parietal lobe Glioma Astrocytoma + + None Died 6.175
Grade IV
17 F 30 Frontal lobe Glioma Oligodendroglioma + None Yes 9.33
18 M 58 Parietal lobe Glioma Glioblastoma + + Steroids Yes 2.49
multiforme
aAny one (+) or more (+ +) of: nuclear pleomorphism; cellularimmaturity; tumour angiogenesis; tumour necrosis. bTo some extent recurrence
depends upon lengths ofclinical follow up or survival. cKemohan grading I-IV (IV = highly malignant) Proc. StaffMeet. Mayo Clin., 24, 71 -75.
Table III Control and unclassifiable samples
Mean ESAF content
Patient Site of Nature of Histological Signs of Drug jig collagen degraded
no. Sex Age specimen specimen features active growth treatment h-' mg-' protein
19 F 24 Corpus White matter Normal white - None 1.12
callosum adjacent to matter
arteriovenous
malformation
20 F 39 Lumbar Tumour of Lipoma - None 0.51
spine spinal cord
21 F 47 Frontal Cortex from Normal - None 0.55
lobe patient with cortex
brain haemorrhage
22 M 35 Temporal Cortex from Contused but - None 0.30
lobe patient with 'normal' cortex
head injury
23 M 55 Cortex Normal cortex - None 0.31
24 M 62 Cortex Cortex obtained Normal cortex - None 0.04
post mortem
25 F 66 Cortex patients died from Normal cortex - None 0.1
myocardial infarction
26 F 77 Cortex Normal cortex - None 0.09
27 F 82 Cortex Normal cortex - None 0.04
Patient
no.
2
3
4
S
6
7
8
9
10
11
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umn and the peak eluting before the procollagenase peak was
collected. This peak contained collagenase inhibited by the
tissue inhibitor of metalloproteinase (TIMP). This complex
has been shown to be activated by ESAF (McLaughlin et al.,
1991). 50fg 3H-labelled collagen was dissolved in 250 tl of
50 mM tris-HCI buffer (pH 7.6) containing 0.2 M NaCl and
0.01 M CaC12 and preincubated for 30 min at 36.5°C. During
this time the collagen gelled. ESAF and latent collagenase in
the above buffer were then added to give a final volume of
500jil and the tube was incubated for 4 h at 36.5°C. During
this time activation by ESAF of the latent collagenase to
form an active enzyme occurred, leading to the degradation
of 3H-labelled collagen and the release of radioactivity into
the buffer. 6 M NaCl in 50 mM tris-HCI buffer was then
added (2501l) to precipitate any undegraded collagen which
had been solubulised during the incubation. After incubation
for a further 30 min, samples were centrifuged at 1700g for
30 min and the radioactivity present in the supernatant was
determined by scintillation counting. Activation was linear
up to the degradation of 30pg collagen. Samples giving
results higher than degradation of 25 gLg collagen were di-
luted and rerun.
Results
All tumours and control brain samples contained detectable
quantities of a diffusible, low molecular mass, latent col-
lagenase activating factor. Gel filtration chromatography of
representative samples on Bio-Gel P-2, showed the active
material to have an apparent molecular mass of 400.
When semi-purified fractions of the biopsy samples were
tested on the chick yolk sac membrane, positive results were
obtained. This indicates the presence of an angiogenic factor
(Figure 1) and suggests the presence of ESAF in these sam-
ples.
The concentration of ESAF in control brain samples were
of the same order as those present in bovine brain and retina
and rat brain, but were considerably less than those found in
human or bovine pineal glands (not shown). This suggests
that there is no apparent species difference between bovine
and human tissue in regard to levels of ESAF. Similar results
have also been obtained from rats (not shown). ESAF levels
present in brain tumours did not relate to the gender of the
patients. However, in control samples there is an indication
that there may be a correlation with low values and age.
Analysis of results from tumours for which information on
their growth characteristics was available indicated that neo-
plasms which were not actively growing had amounts of
ESAF not significantly different from those in control brain
(Figure 2). In contrast tumours showing morphological fea-
tures of active growth had concentrations of ESAF con-
siderably in excess of those found in control brain or in
non-active tumours (P = 0.01 and 0.025 respectively) tu-
mours (Figure 2). Thus in actively growing or malignant
tumours where neovascularisation would be a pre-requisite
for sustained growth ESAF levels were very significantly
raised. Groups of tumours conventionally regarded as malig-
nant (gliomas and astrocytomas) had ESAF levels con-
siderably greater than the control brain samples (P = 0.03) or
brain tumours usually considered to be benign such as
pituitary tumours, meningiomas and acoustic neuromas (Fig-
ure 2). Analysis of tumours according to individual type
indicated that only gliomas contained significantly more
ESAF than control brain samples (Figure 3 and Tables
I-III). Although meningiomas and pituitary tumours had
mean values which were generally greater than control
brains.
Discussion
It is known that tumour tissue contains factors capable of
inducing angiogenic activity (Shing et al., 1985; Folkman &
Klagsbrun, 1987) and the production of many of these fac-
Figure 1 Chick yolk sac membrane showing the response to a, a
sample of ESAF derived from a glioma, b, an ESAF fraction
isolated from a pituitary tumour and c, a control pellet contain-
ing no ESAF. Samples were applied in pellets consisting of
methyl cellulose (4000 centapose: Sigma UK) and were photo-
graphed 24 h later.ESAF AND ANGIOGENESIS 167
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Figure 2 A comparison of ESAF concentrations in control
human brain samples with those found in actively growing and
non-actively growing tumours and with malignant and benign
tumour types. The figures for malignant and benign tumours and
active and non-actively growing tumours are averages of results
in Tables I and II. Both malignant and benign tumours were
significantly different from control brain (P = 0.03 and 0.04
respectively). Actively growing tumours were significantly higher
than non-active tumours (P = 0.025). 1 unit of ESAF = the
amount activating sufficient latent collagenase to degrade 1 fcg
collagen h-'.
tors by tumour cells grown in culture has been confirmed
(Folkman & Klagsbrun, 1987). Thus tumour extracts and
conditioned medium from tumour cell cultures have been
shown to exhibit growth-promoting activity in appropriate
test systems (Folkman, 1977; Klagsbrun et al., 1986). In
some studies the mediators of angiogenic activity have been
isolated and identified. Factors have been isolated which are
closely related to fibroblast growth factors both in structure
and activity (Shing et al., 1985; Klagsbrun et al., 1986). We
have previously isolated tumour ESAF in our laboratories
(Weiss et al., 1979; Lye et al., 1986). Fibroblast growth
factors and ESAF have been extracted from normal adult
tissue and from embryonic tissue. Other putative growth
factors such as transforming growth factor alpha and gastrin
releasing peptide appear only to be found in significant quan-
tities in foetal and neoplastic tissues (Bothwick et al., 1984;
Caffey et al., 1986; Wharton et al., 1979). Few attempts have
been made to compare the actual concentration of growth
factors in normal brain tissue and with those in brain
tumours although it has been shown that the angogenic
activity of cerebrospinal fluid taken from patients with cer-
tain brain tumours is significantly raised compared with that
in the cerebrospinal fluid from control patients (Pousa et al.,
1983).
In the present study we measured the concentrations of
ESAF taken from 'control' (i.e. tumour free) brain tissue and
compared it with that of ESAF in intracranial neoplasms
(Figure 2). Control samples were obtained from patients with
head injury when damaged brain was resected as part of their
treatment or from autopsied patients. It is possible that
angiogenic activity in brain tissue may be lost owing to
biodegradation soon after death, but results obtained from
the two control sources were reasonably comparable except
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Figure 3 A comparison of ESAF levels in control brain with
acoustic neuromas, gliomas, meningiomas and pituitary tumours.
Only the gliomas were significantly different from control brain
(0.03). 1 unit of ESAF = the amount activating sufficient latent
collagenase to degrade 1 fig collagen h-'. A = Control;
B = Acoustic Nerve; C = Glioma; D = Meningioma;
E = Pituitary.
that there appeared to be lower levels in older patients
although this was not significant.
Although our numbers are small it appears that in general
intracranial neoplasms have increased concentrations of
ESAF compared with control samples. There is significant
differences in ESAF levels when intracranial tumours re-
garded as 'actively growing' are compared to 'inactive'
tumours (P = 0.025) (Figure 3). Those tumours considered to
be clinically benign (e.g. acoustic neuromas, pituitary tu-
mours, meningiomas) appear to have significantly lower
concentrations of ESAF when compared with clinically mal-
ignant tumours (such as gliomas) (Figure 3) (P = 0.03). Some
tumour samples obtained from the malignant group had
ESAF levels comparable with those present in the pineal
gland which has the highest level for normal tissues of the
body (Taylor et al., 1988). This is of interest as Korf et al.
(1987) have identified in some brain neoplasms the presence
of genetic markers which were previously thought to be
confined to the pineal gland.
We are unable to comment as to whether there exists a
correlation between ESAF concentration and patient survival
for a given tumour type. This is because there are a large
number of relevant factors we would have to consider, for
example; age on diagnosis; specific histopathological charac-
teristics; sex; treatment with steroid hormones; size and site
of tumour at the time of biopsy and the extent of tumour
removal. The relatively small number of patients and our
short clinical follow-up also limits us in this respect.
It is probably significant, however that as well as those
tumours generally regarded as having an unfavourable prog-
nosis (e.g. glioblastoma multiforme) samples from certain
'benign' tumours had high ESAF levels. Certain menin-
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giomas and pituitary tumours, though usually curable, may
regrow and we were therefore not surprised that samples
from some of these tumours had high ESAF levels. On the
other hand, those tumours such as acoustic neuromas which
almost never recur after total removal had ESAF levels close
to the control values.
We conclude that intracranial neoplasms contain increased
amounts of ESAF compared to normal brain tissue. Further-
more, the more actively growing tumours have higher con-
centrations of ESAF than the more slowly growing benign
tumours. With further study it may be possible to use the
concentration of ESAF in biopsy samples in order to give a
more accurate prognosis for the outcome with respect to
tumour type. It may also one day enable clinicians to devise
therapeutic stratagems to influence tumour growth.
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